Independent register of U.S. FDA drug recalls · updated Oct 13, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

GlipiZIDE Extended-release Tablets

Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.

Terminated Dissolution failure American Health Packaging D-1276-2019
Class II · Moderate risk

TriMix MEDIUM

Lack of assurance of sterility for injectables and solutions intended to be sterile.

Terminated Sterility / contamination Customceutical Compounding D-1262-2019
Class II · Moderate risk

Trimix HIGH

Lack of assurance of sterility for injectables and solutions intended to be sterile.

Terminated Sterility / contamination Customceutical Compounding D-1261-2019
Class II · Moderate risk

Test PROCYP

Lack of assurance of sterility for injectables and solutions intended to be sterile.

Terminated Sterility / contamination Customceutical Compounding D-1260-2019
Class II · Moderate risk

Lipoplex

Lack of assurance of sterility for injectables and solutions intended to be sterile.

Terminated Sterility / contamination Customceutical Compounding D-1257-2019
Class II · Moderate risk

BPlex

Lack of assurance of sterility for injectables and solutions intended to be sterile.

Terminated Sterility / contamination Customceutical Compounding D-1254-2019
Class II · Moderate risk

BPlex

Lack of assurance of sterility for injectables and solutions intended to be sterile.

Terminated Sterility / contamination Customceutical Compounding D-1253-2019
Class II · Moderate risk

Hcg 11

Lack of sterility assurance.

Terminated Sterility / contamination Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy D-1196-2019

Recalls by year